Results 161 to 170 of about 1,461,609 (326)

Natural Killer Cells in Cancer Immunotherapy [PDF]

, 2019
Arndt MA, Chester C, Cortez VS, D'Andrea A, Elsasser D, Ferrini S, Gao Y, Hartmann F, Lotze MT, Miller JS, Orr MT, Seillet C, Soiffer RJ, Soto EO, Weiner LM, Yron I   +15 more
core   +1 more source

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations [PDF]

, 2003
Immunostimulatory CpG oligodeoxynucleotides (ODNs) can enhance the therapeutic effect of monoclonal antibodies (mAbs) by enhancing antibody-dependent cell-mediated cytotoxicity (ADCC).
Bakker, A. (Annie), Bevaart, L., Dahle, C.E., Jansen, M.J.H. (Marco), Ojik, H.H. van, Vugt, M.J. van, Weiner, G.J., Winkel, J.G. van de   +7 more
core  

[Bispecific antibodies: what future?].

Medecine sciences : M/S, 2009
Monoclonal antibodies have emerged as a very successful class of therapeutic agents. In their native format, monoclonal antibodies are monospecific in that they recognize only one epitope, but their Fc domain also binds to FcfR-expressing cells. Attempts to improve the cytotoxicity of antibodies, particularly in the cancer field, have led to the design
Pèlegrin, André, Robert, Bruno
openaire   +2 more sources

Exploring the Potential and Advancements of Circular RNA Therapeutics

Exploration, EarlyView.
Given the remarkable advantages in terms of stability, sustained expression profile, safety, wide range of druggable targets, scalable and cost‐effective manufacturing capabilities, circRNA is currently undergoing intensive investigation for various therapeutic applications such as vaccines, protein replacement, genetic disease treatment, gene therapy,
Lei Wang, Lianqing Wang, Chunbo Dong, Jialong Liu, Guoxin Cui, Shan Gao, Zhida Liu   +6 more
wiley   +1 more source

First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study

Head &Neck, EarlyView.
ABSTRACT Background In Europe, pembrolizumab with or without chemotherapy is the recommended first‐line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with a combined positive score (CPS) ≥ 1. In France, the TPExtreme (TPEx) regimen is preferred for CPS < 1.
Alizée Simon, Cyril Abdeddaim, DucTrung Nguyen, Patrice Gallet, Didier Peiffert, Aurélien Lambert, Lionnel Geoffrois   +6 more
wiley   +1 more source

New bispecific antibodies in diffuse large B-cell lymphoma

Haematologica
The CD20xCD3 T-cell-engaging bispecific antibodies are a highly active new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Adrian G. Minson, Michael J. Dickinson
doaj   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Large scale controlled Fab exchange GMP process to prepare bispecific antibodies

Frontiers in Bioengineering and Biotechnology
Objective: Bispecific antibodies (BsAbs) have demonstrated significant therapeutic impacts for the treatment of a broad spectrum of diseases that include oncology, auto-immune, and infectious diseases.
Xia Yao, Mingquan Xie, Yinyin Ben, Yixiang Zhu, Gaoqiang Yang, Simon Chi Wai Kwong, Zhengliang Zhang, Mark L. Chiu, Mark L. Chiu   +8 more
doaj   +1 more source

A REVIEW ON BISPECIFIC ANTIBODIES

, 2019
Antibodies are widely recognized for their therapeutic potential and subsequently have prompted a lot of interest into their development and application. The structure of monoclonal IgG antibody is represented, with the heavy chains in rose and the light chains in green.
openaire   +1 more source

Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinion

International Journal of Cancer, EarlyView.
What's New? Emerging strategies for the treatment of advanced non‐small cell lung cancer (NSCLC) featuring epidermal growth factor receptor (EGFR) mutations are helping improve patient outcomes. Which strategies are optimal to effectively manage EGFR‐mutant NSCLC, however, remains unclear.
Gee‐Chen Chang, Akhil Kapoor, Chee Khoon Lee, Chunxia Su, Daniel Chan, Guia Elena Imelda Ladrera, Hye Ryun Kim, Mostafa Aziz Sumon, Moushumi Suryavanshi, Sita Andarini, Tatsuya Yoshida, Thanyanan Reungwetwattana, Tuan Khoi Nguyen, Pei Jye Voon   +13 more
wiley   +1 more source